Medivitan Iv Fertigspritze (Cyanocobalamin, Folic Acid, Pyridoxine Hydrochloride)

Cyanocobalamin is a synthetic form of vitamin B12 that, after administration, is converted to the active co‑enzymes methylcobalamin and adenosylcobalamin. These co‑enzymes act as essential cofactors in DNA synthesis, fatty‑acid metabolism and the formation of red blood cells, thereby reversing the metabolic consequences of B12 deficiency.

The dose of Medivitan Iv Fertigspritze is determined by the prescribing clinician based on the patient’s specific deficiency, clinical condition and response to therapy. Healthcare professionals set the appropriate amount, frequency and route of administration for each individual case.

Vitamin B12, folic acid and pyridoxine are essential nutrients during pregnancy and lactation. While no specific contraindication exists, the product should only be used when clearly needed and prescribed by a qualified healthcare provider, who will weigh potential benefits against any theoretical risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if required) and the necessary import documentation.

Medivitan combines three B‑vitamins (B12, B9 and B6) in a single sterile injection, offering broader nutritional support than single‑ingredient B12 products such as hydroxocobalamin. This combination can be advantageous when multiple deficiencies coexist, while single‑ingredient preparations may be preferred for isolated B12 repletion.

The product must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for injection.

Medivitan Iv Fertigspritze is supplied as a sterile solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional using aseptic technique, following the dose and rate prescribed by the treating clinician.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, rare thromboembolic events and, in extremely uncommon cases, methemoglobinemia. Patients should be monitored during and after injection for any signs of allergic response or circulatory compromise.

Patients with known hypersensitivity to cyanocobalamin, folic acid, pyridoxine hydrochloride or any excipients in the formulation should avoid this product. It is also contraindicated in individuals where rapid intravenous administration of incompatible solutions could cause harm.